{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:09:11Z","timestamp":1788930551958,"version":"build-2803163510"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T00:00:00Z","timestamp":1729728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The epidermal growth factor receptor (EGFR) presents a crucial target for combatting cancer mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study employs a suite of computational techniques, including 3D-QSAR, ligand-based virtual screening, molecular docking, fingerprinting analysis, ADME, and DFT-based analyses (MESP, HOMO, LUMO), supplemented by molecular dynamics simulations and MMGB\/PBSA free energy calculations, to explore the binding dynamics of quinazoline derivatives with EGFR. With strong q2 and r2 values from CoMFA and CoMSIA models, our 3D- QSAR models reliably predict EGFR inhibitors\u2019 efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results and Discussion<\/jats:title>\n                    <jats:p>\n                      Utilizing a potent model compound as a reference, an E-pharmacophore model was developed to sift through the eMolecules database, identifying 19 virtual screening hits based on ShapeTanimoto, ColourTanimoto, and TanimotoCombo scores. These hits, assessed via 3D- QSAR, showed pIC\n                      <jats:sub>50<\/jats:sub>\n                      predictions consistent with experimental data. Our analyses elucidate key features essential for EGFR inhibition, reinforced by ADME studies that reveal favorable pharmacokinetic profiles for most compounds. Among the primary phytochemicals examined, potential EGFR inhibitors were identified. Detailed MD simulation analyses on three select ligands\u20141Q1, 2Q17, and VS1\u2014demonstrated their stability and consistent interaction over 200 ns, with MM\/GBSA values corroborating their docking scores and highlighting 1Q1 and VS1\u2019s superior EGFR1 affinity. These results position VS1 as an especially promising lead in EGFR1 inhibitor development, contributing valuable insights towards crafting novel, effective EGFR1 inhibitors.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2024.1399372","type":"journal-article","created":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T00:49:59Z","timestamp":1729730999000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Deciphering quinazoline derivatives\u2019 interactions with EGFR: a computational quest for advanced cancer therapy through 3D-QSAR, virtual screening, and MD simulations"],"prefix":"10.3389","volume":"15","author":[{"given":"Sirajudheen","family":"Anwar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jowaher","family":"Alanazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nafees","family":"Ahemad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shafaq","family":"Raza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahir Ali","family":"Chohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hammad","family":"Saleem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"8003","DOI":"10.1038\/s41598-022-11641-7","article-title":"Modelling liver cancer microenvironment using a novel 3D culture system","volume":"12","author":"Al Hrout","year":"2022","journal-title":"Sci. Rep."},{"key":"B2","doi-asserted-by":"publisher","first-page":"112640","DOI":"10.1016\/j.ejmech.2020.112640","article-title":"Novel quinazoline-based EGFR kinase inhibitors: a review focussing on SAR and molecular docking studies (2015-2019)","volume":"204","author":"Bhatia","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"B4","volume-title":"Amber 12","author":"Case","year":"2012"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1039\/c5mb00860c","article-title":"Molecular modeling studies to characterize N-phenylpyrimidin-2-amine selectivity for CDK2 and CDK4 through 3D-QSAR and molecular dynamics simulations","volume":"12","author":"Chohan","year":"","journal-title":"Mol. Biosyst."},{"key":"B6","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1039\/c5mb00630a","article-title":"Molecular simulation studies on the binding selectivity of 2-anilino-4-(thiazol-5-yl)-pyrimidines in complexes with CDK2 and CDK7","volume":"12","author":"Chohan","year":"","journal-title":"Mol. Biosyst."},{"key":"B7","volume-title":"ACS report shows prostate cancer on the rise, cervical cancer on the decline","author":"Clancy","year":"2023"},{"key":"B8","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/qsar.19880070105","article-title":"Crossvalidation, bootstrapping, and partial least squares compared with multiple regression in conventional QSAR studies","volume":"7","author":"Cramer","year":"1988","journal-title":"Quant. Struct. Act. Relat."},{"key":"B9","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1021\/jm030331x","article-title":"Structural interaction fingerprint (SIFt): a novel method for analyzing three-dimensional protein\u2212 ligand binding interactions","volume":"47","author":"Deng","year":"2004","journal-title":"J. Med. Chem."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e0271602","DOI":"10.1371\/journal.pone.0271602","article-title":"In-silico Investigations of quinine and quinidine as potential Inhibitors of AKR1B1 and AKR1B10: functional and structural characterization","volume":"17","author":"Ejaz","year":"2022","journal-title":"Plos one"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1021\/jm0306430","article-title":"Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy","volume":"47","author":"Friesner","year":"2004","journal-title":"J. Med. Chem."},{"key":"B12","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.str.2012.11.014","article-title":"Insights into the aberrant activity of mutant EGFR kinase domain and drug recognition","volume":"21","author":"Gajiwala","year":"2013","journal-title":"Structure"},{"key":"B13","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/jcc.10379","article-title":"Converging free energy estimates: MM\u2010PB (GB) SA studies on the protein\u2013protein complex Ras\u2013Raf","volume":"25","author":"Gohlke","year":"2004","journal-title":"J. Comput. Chem."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1080\/07391102.2023.2212306","article-title":"3D-QSAR, docking and molecular dynamics simulations of novel Pyrazolo-pyridazinone derivatives as covalent inhibitors of FGFR1: a scientific approach for possible anticancer agents","volume":"42","author":"Hamza","year":"2024","journal-title":"J. Biomol. Struct. Dyn."},{"key":"B15","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.fitote.2017.05.001","article-title":"Pharmaceutical prospects of naturally occurring quinazolinone and its derivatives","volume":"119","author":"He","year":"2017","journal-title":"Fitoterapia"},{"key":"B16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13321-018-0264-0","article-title":"A novel interaction fingerprint derived from per atom score contributions: exhaustive evaluation of interaction fingerprint performance in docking based virtual screening","volume":"10","author":"Jasper","year":"2018","journal-title":"J. Cheminformatics"},{"key":"B17","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3109\/10799893.2014.926925","article-title":"Screening of phytochemicals against protease activated receptor 1 (PAR1), a promising target for cancer","volume":"35","author":"Kakarala","year":"2015","journal-title":"J. Recept. Signal Transduct."},{"key":"B18","doi-asserted-by":"publisher","first-page":"113778","DOI":"10.1016\/j.ejmech.2021.113778","article-title":"Discovery of quinazoline derivatives as a novel class of potent and in vivo efficacious LSD1 inhibitors by drug repurposing","volume":"225","author":"Li","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1002\/1878-0261.12556","article-title":"Improving the efficacy of osteosarcoma therapy: combining drugs that turn cancer cell \u2018don't eat me\u2019signals off and \u2018eat me\u2019signals on","volume":"13","author":"Mohanty","year":"2019","journal-title":"Mol. Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"6582","DOI":"10.1021\/jm300687e","article-title":"Directory of useful decoys, enhanced (DUD-E): better ligands and decoys for better benchmarking","volume":"55","author":"Mysinger","year":"2012","journal-title":"J. Med. Chem."},{"key":"B21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/s0959-8049(01)00231-3","article-title":"EGFR and cancer prognosis","volume":"37","author":"Nicholson","year":"2001","journal-title":"Eur. J. cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e0268269","DOI":"10.1371\/journal.pone.0268269","article-title":"Molecular docking, simulation and binding free energy analysis of small molecules as Pf HT1 inhibitors","volume":"17","author":"Owoloye","year":"2022","journal-title":"Plos one"},{"key":"B23","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1021\/ci300625c","article-title":"Pharmacophore and 3D-QSAR characterization of 6- arylquinazolin-4-amines as Cdc2-like kinase 4 (Clk4) and dual specificity tyrosine-phosphorylation-regulated kinase 1A (Dyrk1A) inhibitors","volume":"53","author":"Pan","year":"2013","journal-title":"J. Chem. Inf. Model."},{"key":"B24","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/jcb.27398","article-title":"Taxifolin prevents postprandial hyperglycemia by regulating the activity of \u03b1\u2010amylase: evidence from an in vivo and in silico studies","volume":"120","author":"Rehman","year":"2019","journal-title":"J. Cell. Biochem."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/07391102.2023.2252092","article-title":"Computer-aided anti-cancer drug discovery of EGFR protein based on virtual screening of drug bank, ADMET, docking, DFT and molecular dynamic simulation studies","author":"Roney","year":"2023","journal-title":"J. Biomol. Struct. Dyn."},{"key":"B36","volume-title":"Maestro","year":"2020"},{"key":"B26","doi-asserted-by":"publisher","first-page":"8103","DOI":"10.1021\/acs.jmedchem.6b00883","article-title":"Tyrosine kinase inhibitors. 20. Optimization of substituted quinazoline and pyrido [3, 4-d] pyrimidine derivatives as orally active, irreversible inhibitors of the epidermal growth factor receptor family","volume":"59","author":"Smaill","year":"2016","journal-title":"J. Med. Chem."},{"key":"B27","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.bmcl.2018.12.020","article-title":"Click chemistry for improvement in selectivity of quinazoline-based kinase inhibitors for mutant epidermal growth factor receptors","volume":"29","author":"Song","year":"2019","journal-title":"Bioorg. and Med. Chem. Lett."},{"key":"B28","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/bs.pmch.2021.01.004","article-title":"Use of molecular docking computational tools in drug discovery","volume":"60","author":"Stanzione","year":"2021","journal-title":"Prog. Med. Chem."},{"key":"B30","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1002\/jmr.2216","article-title":"Exploring the selectivity of a ligand complex with CDK2\/CDK1: a molecular dynamics simulation approach","volume":"25","author":"Tripathi","year":"2012","journal-title":"J. Mol. Recognit."},{"key":"B31","doi-asserted-by":"publisher","first-page":"3222","DOI":"10.1021\/jm8001058","article-title":"Assessment of scaffold hopping efficiency by use of molecular interaction fingerprints","volume":"51","author":"Venhorst","year":"2008","journal-title":"J. Med. Chem."},{"key":"B32","doi-asserted-by":"publisher","first-page":"6652","DOI":"10.1158\/0008-5472.CAN-04-1168","article-title":"A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib) relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells","volume":"64","author":"Wood","year":"2004","journal-title":"Cancer Res."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1399372\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T00:50:01Z","timestamp":1729731001000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1399372\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,24]]},"references-count":31,"alternative-id":["10.3389\/fphar.2024.1399372"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1399372","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,24]]},"article-number":"1399372"}}